Stefanie Flückiger-Mangual (TOLREMO Therapeutics)

article

Looking beyond traditional oncogenic pathways to break cancer resistance

Drug resistance is the leading cause of poor clinical outcomes…

25 September 2024 | By Stefanie Flückiger-Mangual (TOLREMO Therapeutics)

Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways. Blocking transcriptional…

article

Women in Stem with Stefanie Flückiger-Mangual

Stefanie Flückiger-Mangual, Chief Executive Officer, is one of TOLREMO’s scientific…

6 May 2024 | By Stefanie Flückiger-Mangual (TOLREMO Therapeutics)

Stefanie Flückiger-Mangual, Chief Executive Officer, is one of TOLREMO’s scientific founders and an expert in drug resistance in cancer therapy. She is a biomedical scientist and biochemist by training (University of Fribourg and ETH Zurich, Switzerland) and holds a PhD in Molecular and Translational Biomedicine from ETH Zurich. She led…